These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19390710)

  • 1. Prognostic value of the collagen volume fraction in hypertrophic cardiomyopathy.
    Arteaga E; de Araújo AQ; Bernstein M; Ramires FJ; Ianni BM; Fernandes F; Mady C
    Arq Bras Cardiol; 2009 Mar; 92(3):210-4, 216-20. PubMed ID: 19390710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.
    Moravsky G; Ofek E; Rakowski H; Butany J; Williams L; Ralph-Edwards A; Wintersperger BJ; Crean A
    JACC Cardiovasc Imaging; 2013 May; 6(5):587-96. PubMed ID: 23582356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Myocardial fibrosis in patients with hypertrophic cardiomyopathy and high risk for sudden death].
    Shiozaki AA; Senra T; Arteaga E; Pita CG; Martinelli Filho M; Avila LF; Parga Filho JR; Mady C; Rochitte CE
    Arq Bras Cardiol; 2010 Apr; 94(4):535-40. PubMed ID: 20339815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes of left ventricular myocardial collagen fibers and osteopontin expression in hypertrophic cardiomyopathy].
    Tang DW; Lin GS; Huang JL; Liu C; Hao B; Yu YG; Kong XP; Quan L; Liao XB; Luo B
    Fa Yi Xue Za Zhi; 2012 Aug; 28(4):247-51. PubMed ID: 23033660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Yang C; Qiao S; Song Y; Liu Y; Tang Y; Deng L; Yuan J; Hu F; Yang W
    Cardiovasc Pathol; 2019; 43():107150. PubMed ID: 31639652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy.
    Münch J; Avanesov M; Bannas P; Säring D; Krämer E; Mearini G; Carrier L; Suling A; Lund G; Patten M
    J Card Fail; 2016 Oct; 22(10):845-50. PubMed ID: 27018569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Implication of First-Degree Atrioventricular Block in Patients With Hypertrophic Cardiomyopathy.
    Higuchi S; Minami Y; Shoda M; Shirotani S; Saito C; Haruki S; Gotou M; Yagishita D; Ejima K; Hagiwara N
    J Am Heart Assoc; 2020 Mar; 9(6):e015064. PubMed ID: 32146896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.
    O'Hanlon R; Grasso A; Roughton M; Moon JC; Clark S; Wage R; Webb J; Kulkarni M; Dawson D; Sulaibeekh L; Chandrasekaran B; Bucciarelli-Ducci C; Pasquale F; Cowie MR; McKenna WJ; Sheppard MN; Elliott PM; Pennell DJ; Prasad SK
    J Am Coll Cardiol; 2010 Sep; 56(11):867-74. PubMed ID: 20688032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure.
    Dai Z; Aoki T; Fukumoto Y; Shimokawa H
    J Cardiol; 2012 Nov; 60(5):416-21. PubMed ID: 22867802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
    Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
    JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
    Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia.
    Kirk P; Sheppard M; Carpenter JP; Anderson L; He T; St Pierre T; Galanello R; Catani G; Wood J; Fucharoen S; Porter JB; Walker JM; Forni GL; Pennell DJ
    J Cardiovasc Magn Reson; 2017 Mar; 19(1):36. PubMed ID: 28343449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death.
    Basso C; Thiene G; Mackey-Bojack S; Frigo AC; Corrado D; Maron BJ
    Eur Heart J; 2009 Jul; 30(13):1627-34. PubMed ID: 19406869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
    McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
    J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A4 and P53 in myocardial collagen fibers of hypertrophic cardiomyopathy : Expression and clinical significance.
    Qi X; Han J; Zhao P; Dong X; Gong S
    Herz; 2016 Sep; 41(6):530-3. PubMed ID: 26781584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age.
    Maron BJ; Rowin EJ; Casey SA; Haas TS; Chan RH; Udelson JE; Garberich RF; Lesser JR; Appelbaum E; Manning WJ; Maron MS
    Circulation; 2013 Feb; 127(5):585-93. PubMed ID: 23275385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.